|
|
||||||||
1 Rammelkamp Center for Education and Research, 5 Heart and Vascular Research Center, and 6 Department of Epidemiology and Biostatistics, MetroHealth Campus, Departments of 8 Physiology and Biophysics, 4 Biochemistry and 2 Cardiac Bioelectricity Research and Training Center, Case Western Reserve University, Cleveland, Ohio 44109; and 3 Molecular Cardiology Laboratories, Fondazione Salvatore Maugeri and 7 Department of Cardiology, University of Pavia, Policlinico San Matteo, Istituto di Ricovero e Cura a Carattere Scientifico, 27100 Pavia, Italy
| |
ABSTRACT |
|---|
|
|
|---|
Hereditary long QT syndrome (hLQTS) is a heterogeneous genetic disease characterized by prolonged QT interval in the electrocardiogram, recurrent syncope, and sudden cardiac death. Mutations in the cardiac potassium channel HERG (KCNH2) are the second most common form of hLQTS and reduce the delayed rectifier K+ currents, thereby prolonging repolarization. We studied a novel COOH-terminal missense mutation, HERG R752W, which segregated with the disease in a family of 101 genotyped individuals. When the mutant cRNA was expressed in Xenopus oocytes it produced enhanced rather than reduced currents. Simulations using the Luo-Rudy model predicted minimal shortening rather than prolongation of the cardiac action potential. Consequently, a normal or shortened QT interval would be expected in contrast to the long QT observed clinically. This anomaly was resolved by our observation that the mutant protein was not delivered to the plasma membrane of mammalian cells but was retained intracellularly. We found that this trafficking defect was corrected at lower incubation temperatures and that functional channels were now delivered to the plasma membrane. However, trafficking could not be restored by chemical chaperones or E-4031, a specific blocker of HERG channels. Therefore, HERG R752W represents a new class of trafficking mutants in hLQTS. The occurrence of different classes of misprocessed channels suggests that a unified therapeutic approach for altering HERG trafficking will not be possible and that different treatment modalities will have to be matched to the different classes of trafficking mutants.
human ether-á-go-go-related gene; trafficking; K+ channel; arrhythmia
| |
INTRODUCTION |
|---|
|
|
|---|
HEREDITARY LONG QT SYNDROME (LQTS) is a heterogeneous genetic disease that predisposes affected individuals to life-threatening arrhythmias (25, 26). The disease is caused by mutations in five known genes, of which four encode potassium channels (1, 19, 19a, 19b). The second most common form, LQT2, is linked to mutations in the cardiac potassium channel HERG on human chromosome 7 (22). Mutations in HERG have been described in both cytoplasmic termini (2, 5) as well as transmembrane domains (e.g., Refs. 10, 21, 30) and result in three classes of defects: 1) channels with abnormal gating and reduced currents (21, 30), 2) channels that reach the plasma membrane but do not conduct current (30), and 3) channels that are retained in the endoplasmic reticulum (ER) (10, 30, 31). Mutations in classes 1 and 2 reduce expression levels even more if there is dominant-negative suppression of functional channels produced by the wild-type (WT) allele (21). Some mutations in class 3 are hypomorphic, i.e., they show severely impaired trafficking where the majority of channel protein is retained in the ER and few channels leak out to the plasma membrane producing small currents at 37°C (10, 31).
Mutations defective in trafficking have been reported for other membrane proteins including minK (3), P-glycoprotein (14), aquaporins (27) and the cystic fibrosis transmembrane conductance regulator (CFTR) (11, 12). Loss of function associated with trafficking mutations in CFTR (8), P-glycoprotein (14), and aquaporins (27) may be rescued by synthesis at reduced temperature (8, 14, 31), by overexpression (6), by chemical chaperones such as glycerol and dimethylsulfoxide (4, 24, 27), or by specific drugs binding to misprocessed membrane proteins (15, 31). For the hypomorphic HERG mutation N470D, it was shown more recently that trafficking can be improved not only by incubation at low temperature but also in the presence of osmolytes or the specific channel ligand E-4031 (31).
In a large LQT2 family we found a novel COOH-terminal missense mutation, HERG R752W, which was retained in the ER. The mutant protein was "rescued" and delivered to the plasma membrane after incubation at reduced temperatures in mammalian cells or after expression in Xenopus oocytes. However, trafficking could not be restored by incubation with chemical chaperones or E-4031, a specific blocker of HERG channels. When trafficking was corrected, HERG R752W channels conducted enhanced currents that slightly shortened the cardiac action potential simulated by the Luo-Rudy model of a mammalian ventricular myocyte.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Molecular biology and electrophysiology.
HERG R752W was prepared by overlap extension PCR, verified by
sequencing, and subcloned as a Xho I-BamH I
fragment into either full-length HERG-pSP64 or HERG-pCDNA3. In vitro
RNA synthesis and oocyte injections were performed as described
(9). Production and size of full-length cRNA was verified
by denaturing agarose gel electrophoresis, and cRNA concentrations were
determined with Ribogreen RNA quantitation kit (Molecular Probes). In
Xenopus oocytes, currents were recorded 2-7 days after
injection using a Dagan 8500 two-electrode voltage-clamp amplifier.
Current and voltage electrodes were filled with 3 M KCl and had
resistances of ~1 M
. The composition of the bath solution used to
perfuse oocytes was (in mM) 96 NaCl, 5 KCl, 1.8 CaCl2, 1.0 MgCl2, and 5 HEPES (K+ Ringer solution, pH
7.4). Cell-attached macropatch recordings in oocytes were performed as
described previously (9). Patch pipettes (resistance,
0.2-0.6 M
) were filled with K+ Ringer solution, and
the depolarizing bath solution had the following composition (in mM):
100 KCl, 10 EGTA, 1 EDTA, and 10 HEPES (pH 7.4). For
electrophysiological experiments in HEK293 cells, transient transfections were carried out with the Ca2+ phosphate
method. After transfection, cells were incubated for 48 h at
either 26 or 37°C. For visual identification, HEK cells were
cotransfected with CD8 antigen (1:5 ratio) and incubated before
recordings with beads coated with CD8 antibodies (Dynal). Patch
pipettes were filled with (in mM) 100 K-aspartate, 20 KCl, 2 MgCl2, 1 CaCl2, 10 EGTA, and 10 HEPES (pH 7.2).
The extracellular solution had the following composition (in mM): 140 NaCl, 5 KCl, 1 MgCl2, 1.8 CaCl2, 10 HEPES, and
10 glucose (pH 7.4). No leak subtraction was applied. All current
recordings were performed at room temperature (20-22°C). pClamp
software (Axon Instruments) was used for the generation of
voltage-clamp protocols and data acquisition. Data are presented as
means ± SE of n experiments.
Simulations. The simulations in this study were conducted using the Luo-Rudy model, a theoretical dynamic model of a mammalian ventricular action potential. The model includes membrane ionic channel currents that are formulated mathematically using the Hodgkin-Huxley approach as well as ionic pumps and exchangers. It also includes processes that regulate intracellular concentration changes of Na+, K+, and Ca2+ (7, 16, 29). For the purpose of this study, the formulation of the fast delayed rectifier potassium current, IKr, was modified to fit our experimental voltage clamp data obtained from HERG-WT and HERG-R752W channels. All kinetic parameters were normalized to 37°C with a Q10 of 3. The basic protocol for action potential simulations involved stimulation of the model cell 10 times at a constant cycle length (CL) of 1,000 ms.
Antibodies. The anti-HERG polyclonal antibody used in Western blots and for immunostaining was generated in rabbits against a glutathione-S-transferase (GST) fusion protein containing the last 112 amino acids of HERG (residues 1048-1159). HERG antiserum was either purified on an affinity column consisting of a short COOH-terminal peptide corresponding to HERG residues 1102-1121 (TLTLDSLSQVSQFMACEELP) or the entire fusion protein.
Western blot analysis and immunostaining. For Western blotting, HEK 293 cells were transfected with Lipofectamine/Plus as recommended by manufacturer (Life Technologies). Forty-eight hours after transfection, cells were solubilized for 1 h at 4°C in lysis buffer [50 mM Tris · HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100], containing protease inhibitor mix (Complete, Roche Biochemicals). To isolate a crude membrane fraction, oocytes were homogenized in 0.3 M sucrose and 10 mM NaPO4 (pH 7.4) supplemented with protease inhibitor mix (Complete). After removal of debris and nuclei (3,000 g, 10 min), the supernatant was spun at 50,000 g for 1 h at 4°C to pellet membranes. Protein concentrations were determined by the bicinchoninic acid method (Pierce). For Western blotting, proteins were separated on 8% SDS polyacrylamide gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked overnight with 5% nonfat dry milk in PBS plus 0.1% Tween and immunoblotted with polyclonal rabbit anti-HERG antibody (1:200 dilution; 1 h at RT) followed by horseradish peroxidase-conjugated secondary antibody (1:3,000; 1 h at RT; Amersham Pharmacia Biotech). Western blots were developed with the ECL-Plus detection system (Amersham Pharmacia). For immunostaining, transiently transfected COS cells were grown on coverslips and fixed with 4% paraformaldehyde in PBS 48 h after transfection. After fixing, cells were permeabilized with 0.1% Triton X-100 in PBS, blocked with 5% nonfat dry milk in PBS, and stained at 4°C overnight with anti-HERG antibody (1:100). The tetramethylrhodamine isothiocyanate-conjugated secondary antibody (1:100; Jackson Labs) was added for 2 h at room temperature. For observation, coverslips were mounted on slides with Vectashield (Vector Labs).
| |
RESULTS |
|---|
|
|
|---|
HERG R752W was identified in a 31-yr-old woman with a history of syncope who died suddenly. Twenty-six of 101 genotyped family members were found to be carriers. Of these, 17 had prolonged QT intervals (QTc > 0.44ms) and 6 had a history of syncope.
Characterization of HERG R752W currents in Xenopus oocytes.
The cellular phenotype of LQT mutations is often studied by measuring
currents expressed in Xenopus oocytes. After injection of
equivalent amounts of cRNA, we were surprised to find that mutant HERG
R752W channels produced larger outward currents than WT channels (Fig.
1, A and B). Both
WT and R752W produced typical bell-shaped isochronal current-voltage
(I-V) relationships (Fig. 1C). For R752W, the
amplitudes were larger and the I-V curve was shifted to more
hyperpolarized potentials. To evaluate the shift, maximum tail currents
elicited at
90 mV were used to calculate a correction factor to
account for small differences in expression levels (Fig.
1D). Compared with the corrected WT, I-V curve
threshold and peak for R752W remained shifted (Fig. 1C),
suggesting that altered gating properties contributed importantly to
the larger currents of R752W. Coinjection of equal amounts of WT and
R752W cRNA produced a summation of current amplitudes at potentials more positive than
20 mV. At more hyperpolarized potentials, current
amplitudes from the combined injection were not significantly changed
from R752W alone despite the increased amount of cRNA injected. One
explanation might be that below
20 mV, activation rates for R752W/WT
heteromultimers are very different from homomultimeric channels (see
Fig. 2C), thereby producing a
complex interaction with current amplitudes as measured in Fig.
1C. At more positive potentials, however, activation rates
converge, and consequently current amplitudes increase as expected for
coinjection experiments. Nonetheless, our results show clearly that
mutant channels do not suppress WT currents in a dominant-negative
manner.
|
|
20 and 0 mV but approximated values measured for
R752W alone at +20 and +40 mV (Fig. 2C). Current
deactivation was fit by the sum of two exponentials. Both time
constants were accelerated in mutant channels (Fig. 2, E and
F). Coinjections of equal amounts of WT and R752W produced
intermediate values for slow time constants. For the faster process,
coinjections approached values measured for R752W alone at potentials
between
90 and
120 mV. The faster deactivation rates measured in
mutant channels might reduce outward currents during the terminal
repolarization phase of the cardiac action potential and cause
prolongation of the QT interval. On the other hand, the faster
activation rates of R752W predicted more current during the plateau and
a tendency to shorten the cardiac action potential.
Simulations of the effects of WT HERG R752W current on the cardiac
action potential.
Because the kinetic differences were ambiguous with respect to changes
of the QT interval, the effects were simulated with the Luo-Rudy model
of the cardiac ventricular action potential (7, 16, 29).
The mathematical formulation of the rapid delayed rectifier,
IKr, reproduced the kinetic data of Figs. 1 and
2 for WT and mutant channels. Figure 3
shows action potentials and IKr currents
computed from WT and mutant cells. Due to faster activation kinetics,
mutant IKr was larger than WT
IKr and produced a minor shortening of action
potential duration.
|
Reconciling mutant HERG currents with QT prolongation.
The discordance between the cellular phenotype in Xenopus
oocytes and the prolonged QT interval observed clinically recalled the
temperature sensitivity of the CFTR
F508 mutant (8).
Therefore, we expressed HERG R752W in mammalian HEK293 cells at a
physiological temperature of 37°C and used whole cell patch clamp
recordings to characterize mutant currents. We were not able to detect
any HERG-like outward current in HEK293 cells transfected with R752W, although WT current was obtained routinely under identical experimental conditions (Fig. 4, A and
B). Because mutant currents were elicited in
Xenopus oocytes and because oocytes are maintained at lower temperatures than mammalian cells, we tested the effect of reduced incubation temperature on expression of R752W. After incubation for 2 days at 26°C, large whole cell HERG currents were recorded in cells
transfected with R752W cDNA and had an electrophysiological profile
similar to that described in Xenopus oocytes (Fig. 4, C and D).
|
|
F508 CFTR
protein were partially corrected by chemical chaperones such as
glycerol (4, 24) or transcriptional regulators such as
4-phenylbutyrate (4-PB) (20), we tested whether these
agents might correct the malfunction of R752W processing. We evaluated the effects of 7.5, 10, and 12.5% glycerol added to the incubation medium using Western blots. In none of these experiments did we observe
any change in the glycosylation pattern of R752W incubated at 37°C,
whereas protein synthesis was progressively decreased with higher
glycerol concentrations (Fig. 5C). Patch clamp recordings also failed to detect R752W currents in cells incubated for 2 days at
37°C at the different glycerol concentrations. However, cell
viability was not dramatically impaired, because HERG WT currents could
be recorded from cells incubated with 10% glycerol (data not shown).
Similarly, incubation with DMSO (140 and 280 mM) and trimethylamine
N-oxide (100 and 200 mM) did not improve channel trafficking
(data not shown). Furthermore, treatment of R752W transfected cells
with 2.5 mM 4-PBA at 37°C had no effect on processing and no currents
were detectable although protein synthesis was substantially increased
(Fig. 5C). More recently it was reported that the
antiarrhythmic drug E-4031 improves trafficking of the hypomorphic
mutation HERG N470D (31). In contrast, HERG R752W channel
protein synthesized at 37°C was present only in the core-glycosylated
form when transfected cells were treated for 24 h in the presence
of 5 µM E-4031 (Fig. 5C).
| |
DISCUSSION |
|---|
|
|
|---|
The electrophysiological phenotype of the processed R752W mutant is characterized by mild changes in gating properties that do not translate into prolongation of the cardiac action potential and hence the QT interval as judged by our simulations. The accelerated activation and deactivation kinetics of R752W resembles mutations described previously in the NH2-terminal PAS (Per, Arnt, and Sim) domain of the channel protein, especially HERG R56Q (5). In prokaryotes, PAS domains serve as sensors for light and redox potential (32) and in HERG channels it is thought that the PAS domain is attached to the intracellular mouth of the channel protein, thereby regulating channel gating (17, 28). Accordingly, structure-function studies suggested that mutations in the PAS domain disrupted interactions with amino acid residues in the cytoplasmic S4-S5 linker (23). We speculate that R752 may interact in a similar manner with the activation machinery of HERG or, alternatively, may stabilize the interaction of the PAS domain with the S4-S5 linker.
Our electrophysiological studies show that mutant channels function with slightly altered kinetics. The Luo-Rudy simulations suggest that these channels generate a normal action potential once they reach the plasma membrane, indicating that the clinically observed prolonged QT interval does not reflect altered channel kinetics. At physiological temperatures, however, mutant channels cannot pass quality control processes of the ER and do not reach the plasma membrane. At reduced temperatures where protein folding might be altered, HERG R752W attained a conformation that ultimately permitted exit from the ER. The molecular mechanism responsible for this conformational stabilization is not understood and remains to be analyzed in the future.
The coexpression experiments suggest that at 37°C, mutant channels are arrested in conformations that do not allow for the assembly of HERG tetramers, because neither dominant-negative current suppression nor a significant increase in current amplitudes has been observed. This interpretation is in line with previous reports that the COOH terminus is critical for HERG assembly and expression (13).
We explored whether chemical chaperones known to stabilize temperature-sensitive mutants were effective in correcting the trafficking defect associated with HERG R752W. Glycerol has been described as the most effective chemical chaperone to correct misfolding of CFTR, P-glycoprotein, or aquaporin mutant channels (14, 24, 27), and at molar concentrations we found no increase in the delivery of mutant protein to the cell membrane. In contrast, glycerol seemed to decrease the overall synthesis of mutant protein. An explanation might be that the efficacy of chemical chaperones not only depends on the particular cell line used for heterologous expression but also on the protein domain affected by a mutation and on the chemical nature of the amino acid side chain introduced (24). In CFTR it was shown that glycerol promoted the maturation of mutants K464R and K464A but not of K464W, a mutation with an amino acid substitution similar to the one analyzed in HERG R752W.
The failure of glycerol treatment to facilitate trafficking of HERG R752W was surprising because trafficking of HERG N470D, a hypomorphic mutation in the transmembrane domain of HERG, was improved by incubation in 10% glycerol (31). Similarly, the antiarrhythmic drug E-4031 facilitated trafficking of HERG N470D, but was ineffective on the R752W mutant. These differences suggest that HERG R752W represents a new and different class of misprocessed mutants with distinct mechanisms responsible for retention of mutations localized to different functional domains of the HERG channel protein. This observation is important because it makes a unifying approach for altering HERG trafficking unlikely. On the contrary, functionally different classes of mutations will have to be targeted separately in any attempt to discover novel and useful chaperones for misprocessed channel proteins.
Because chemical chaperones were not effective in HERG R752W, we complemented our experiments by treating HEK cells expressing HERG R752W with 4-PB, an analog of the transcriptional regulator butyrate. In analogy to experiments in CFTR, we tried to boost expression of HERG R752W to force the mutant by mass action past the ER to the plasma membrane (20). Although synthesis of HERG R752W was substantially enhanced, we were not able to detect fully glycosylated mature protein. This might indicate that at 37°C, only a small portion, if any, of the mutant protein was exportable and that the quality control system was not saturated.
In summary, HERG R752W is the first member of a novel class of temperature-sensitive trafficking mutants that do not express any current at 37°C and are resistant to rescue by osmolytes or specific channel ligands. The clinically observed prolonged QT interval is explained best by a reduction of the delayed rectifier current IKr caused by the inability of the mutant protein to reach the plasma membrane at body temperature. Thus, although HERG R752W behaves as a loss-of-function mutation, there is one major difference from hLQT mutations reported heretofore: HERG R752W encodes a fully functional channel protein if it can be made to reach the plasma membrane. For this reason, further efforts should aim at discovering novel and useful chemical chaperones.
| |
ACKNOWLEDGEMENTS |
|---|
This study was supported by National Heart, Lung, and Blood Institute (NHLBI) Grants HL-49054 and HL-33343 to Y. Rudy and by NHBLI Grants HL-36930, HL-55404, and HL-60925 and National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-54178 to A. M. Brown.
| |
FOOTNOTES |
|---|
Present address of D. Thomas: Kardiologie, Universitaetsklinik Heidelberg, Heidelberg, Germany.
Address for reprint requests and other correspondence: A. M. Brown and E. Ficker, Rammelkamp Center, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109 (E-mail: abrown{at}research.metrohealth.org).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 14 December 1999; accepted in final form 28 April 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Abbott, GW,
Sesti F,
Splawski I,
Buck ME,
Lehmann MH,
Timothy KW,
Keating MT,
and
Goldstein SA.
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia.
Cell
97:
175-187,
1999[ISI][Medline].
2.
Berthet, M,
Denjoy I,
Donger C,
Demay L,
Hammoude H,
Klug D,
Schulze-Bahr E,
Richard P,
Funke H,
Schwartz K,
Coumel P,
Hainque B,
and
Guicheney P.
C-terminal HERG mutations. The role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence.
Circulation
99:
1464-1470,
1999
3.
Bianchi, L,
Shen Z,
Dennis A,
Priori SG,
Napolitano C,
Ronchetti E,
Bryskin R,
Schwartz PJ,
and
Brown AM.
Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and trafficking in long QT syndrome.
Hum Mol Genet
8:
1499-1507,
1999
4.
Brown, CR,
Hong-Brown LQ,
Biwersi J,
Verkman AS,
and
Welch WJ.
Chemical chaperones correct the mutant phenotype of the dF508 cystic fibrosis transmembrane conductance regulator protein.
Cell Stress Chaperones
1:
117-125,
1996[ISI][Medline].
5.
Chen, J,
Zou A,
Splawski I,
Keating MT,
and
Sanguinetti MC.
Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation.
J Biol Chem
274:
10113-10118,
1999
6.
Cheng, SH,
Fang SL,
Zabner J,
Marshall J,
Piraino S,
Schiavi SC,
Jefferson DM,
Welsh MJ,
and
Smith AE.
Functional activation of the cystic fibrosis trafficking mutant dF508-CFTR by overexpression.
Am J Physiol Lung Cell Mol Physiol
268:
L615-L624,
1995
7.
Clancy, CE,
and
Rudy Y.
Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia.
Nature
400:
566-569,
1999[Medline].
8.
Denning, GM,
Anderson MP,
Amara JF,
Marshall J,
Smith AE,
and
Welsh MJ.
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.
Nature
358:
761-764,
1992[Medline].
9.
Ficker, E,
Jarolimek W,
Kiehn J,
Baumann A,
and
Brown AM.
Molecular determinants of dofetilide block of HERG K+ channels.
Circ Res
82:
386-396,
1998
10.
Furutani, M,
Trudeau MC,
Hagiwara N,
Seki A,
Gong Q,
Zhou Z,
Imamura S,
Nagashima H,
Kasanuki H,
Takao A,
Momma K,
January CT,
Robertson GA,
and
Matsuoka R.
Novel mechanism associated with an inherited cardiac arrhythmia.
Circulation
99:
2290-2294,
1999
11.
Kerem, B,
Rommens JM,
Buchanan JA,
Markiewicz D,
Cox TK,
Chakravarti A,
Buchwald M,
and
Tsui LC.
Identification of the cystic fibrosis gene: genetic analysis.
Science
245:
1073-1080,
1989
12.
Kopito, RR.
Biosynthesis and degradation of CFTR.
Physiol Rev
79:
S167-S173,
1999.
13.
Kupershmidt, S,
Snyders DJ,
Raes A,
and
Roden DM.
A K+ channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current.
J Biol Chem
273:
27231-27235,
1998
14.
Loo, TW,
and
Clarke DM.
Prolonged association of temperature-sensitive mutants of human P-glycoprotein with calnexin during biogenesis.
J Biol Chem
269:
28683-28689,
1994
15.
Loo, TW,
and
Clarke DM.
Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators.
J Biol Chem
272:
709-712,
1997
16.
Luo, CH,
and
Rudy Y.
A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes.
Circ Res
74:
1071-1096,
1994
17.
Morais Cabral, JH,
Lee A,
Cohen SL,
Chait BT,
Li M,
and
MacKinnon R.
Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain.
Cell
95:
649-655,
1998[ISI][Medline].
18.
Petrecca, K,
Atanasiu R,
Akhavan A,
and
Shrier A.
N-linked glycosylation sites determine HERG channel surface membrane expression.
J Physiol (Lond)
515:
41-48,
1999
19.
Priori, SG,
Barhanin J,
Hauer RNW,
Haverkamp W,
Jongsma HJ,
Kleber AG,
McKenna WJ,
Roden DM,
Rudy Y,
Schwartz K,
Schwartz PJ,
Towbin JA,
and
Wilde AM.
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management. Part I and II.
Circulation
99:
518-528,
1999
19a.
Priori, SG,
Barhanin J,
Hauer RNW,
Haverkamp W,
Jongsma HJ,
Kleber AG,
McKenna WJ,
Roden DM,
Rudy Y,
Schwartz K,
Schwartz PJ,
Towbin JA,
and
Wilde AM.
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management. Part III.
Circulation
99:
674-681,
1999
19b.
Priori, SG,
Barhanin J,
Hauer RNW,
Haverkamp W,
Jongsma HJ,
Kleber AG,
McKenna WJ,
Roden DM,
Rudy Y,
Schwartz K,
Schwartz PJ,
Towbin JA,
and
Wilde AM.
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management.
Eur Heart J
20:
179-195,
1999.
20.
Rubenstein, RC,
Egan ME,
and
Zeitlin PL.
In vitro pharmacological restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing dF508-CFTR.
J Clin Invest
100:
2457-2465,
1997[ISI][Medline].
21.
Sanguinetti, MC,
Curran ME,
Spector PS,
and
Keating MT.
Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia.
Proc Natl Acad Sci USA
93:
2208-2212,
1996
22.
Sanguinetti, MC,
Jiang C,
Curran ME,
and
Keating MT.
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
Cell
81:
299-307,
1995[ISI][Medline].
23.
Sanguinetti, MC,
and
Xu PC.
Mutations of the S4-S5 linker alter activation properties of HERG potassium channels expressed in Xenopus oocytes.
J Physiol (Lond)
514:
667-675,
1999
24.
Sato, S,
Ward CL,
Krouse ME,
Wine JJ,
and
Kopito RR.
Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation.
J Biol Chem
271:
635-639,
1996
25.
Schwartz, PJ.
Idiopathic long QT syndrome: progress and questions.
Am Heart J
109:
399-411,
1985[ISI][Medline].
26.
Schwartz, PJ,
Priori SG,
and
Napolitano C.
Long QT syndrome.
In: Cardiac Electrophysiology: From Cell to Bedside (3rd ed.), edited by Zipes DP,
and Jalife J.. Philadelphia, PA: Saunders, 2000, p. 597-615.
27.
Tamarappoo, BK,
and
Verkman AS.
Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones.
J Clin Invest
101:
2257-2267,
1998[ISI][Medline].
28.
Wang, J,
Trudeau MC,
Zappia AM,
and
Robertson GA.
Regulation of deactivation by an amino terminal domain in human ether-a-go-go gene potassium channels.
J Gen Physiol
112:
637-647,
1998
29.
Zeng, J,
Laurita KR,
Rosenbaum DS,
and
Rudy Y.
Two components of the delayed rectifier K+ current in ventricular myocytes of the guinea pig type. Theoretical formulation and their role in repolarization.
Circ Res
77:
140-152,
1995
30.
Zhou, Z,
Gong Q,
Epstein ML,
and
January CT.
HERG channel dysfunction in human long QT syndrome.
J Biol Chem
273:
21061-21066,
1998
31.
Zhou, Z,
Gong Q,
and
January CT.
Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome.
J Biol Chem
274:
31123-31126,
1999
32.
Zhulin, IB,
Taylor BL,
and
Dixon R.
PAS domain S-boxes in Archaea, Bacteria and sensors for oxygen and redox.
Trends Biochem Sci
22:
331-333,
1997[ISI][Medline].
This article has been cited by other articles:
![]() |
T. A. Beery, K. A. Shooner, and D. W. Benson Neonatal Long QT Syndrome Due to a De Novo Dominant Negative hERG Mutation Am. J. Crit. Care., July 1, 2007; 16(4): 416 - 412. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Phartiyal, E. M. C. Jones, and G. A. Robertson Heteromeric Assembly of Human Ether-a-go-go-related Gene (hERG) 1a/1b Channels Occurs Cotranslationally via N-terminal Interactions J. Biol. Chem., March 30, 2007; 282(13): 9874 - 9882. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-u. Choe, E. Schulze-Bahr, A. Neu, J. Xu, Z. I. Zhu, K. Sauter, R. Bahring, S. Priori, P. Guicheney, G. Monnig, et al. C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3{epsilon} Hum. Mol. Genet., October 1, 2006; 15(19): 2888 - 2902. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Anderson, B. P. Delisle, B. D. Anson, J. A. Kilby, M. L. Will, D. J. Tester, Q. Gong, Z. Zhou, M. J. Ackerman, and C. T. January Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism Circulation, January 24, 2006; 113(3): 365 - 373. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D.C. Paulussen, A. Raes, R. J. Jongbloed, R. A.H.J. Gilissen, A. A.M. Wilde, D. J. Snyders, H. J.M. Smeets, and J. Aerssens HERG mutation predicts short QT based on channel kinetics but causes long QT by heterotetrameric trafficking deficiency Cardiovasc Res, August 15, 2005; 67(3): 467 - 475. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Akhavan, R. Atanasiu, T. Noguchi, W. Han, N. Holder, and A. Shrier Identification of the cyclic-nucleotide-binding domain as a conserved determinant of ion-channel cell-surface localization J. Cell Sci., July 1, 2005; 118(13): 2803 - 2812. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gouas, C. Bellocq, M. Berthet, F. Potet, S. Demolombe, A. Forhan, R. Lescasse, F. Simon, B. Balkau, I. Denjoy, et al. New KCNQ1 mutations leading to haploinsufficiency in a general population: Defective trafficking of a KvLQT1 mutant Cardiovasc Res, July 1, 2004; 63(1): 60 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Delisle, B. D. Anson, S. Rajamani, and C. T. January Biology of Cardiac Arrhythmias: Ion Channel Protein Trafficking Circ. Res., June 11, 2004; 94(11): 1418 - 1428. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Krumerman, X. Gao, J.-S. Bian, Y. F. Melman, A. Kagan, and T. V. McDonald An LQT mutant minK alters KvLQT1 trafficking Am J Physiol Cell Physiol, June 1, 2004; 286(6): C1453 - C1463. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Anson, M. J. Ackerman, D. J. Tester, M. L. Will, B. P. Delisle, C. L. Anderson, and C. T. January Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2434 - H2441. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J Paavonen, H. Chapman, P. J Laitinen, H. Fodstad, K. Piippo, H. Swan, L. Toivonen, M. Viitasalo, K. Kontula, and M. Pasternack Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG) Cardiovasc Res, September 1, 2003; 59(3): 603 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Paulussen, A. Raes, G. Matthijs, D. J. Snyders, N. Cohen, and J. Aerssens A Novel Mutation (T65P) in the PAS Domain of the Human Potassium Channel HERG Results in the Long QT Syndrome by Trafficking Deficiency J. Biol. Chem., December 6, 2002; 277(50): 48610 - 48616. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Marr, D. G. Bichet, S. Hoefs, P. J. M. Savelkoul, I. B. M. Konings, F. de Mattia, M. P. J. Graat, M.-F. Arthus, M. Lonergan, T. M. Fujiwara, et al. Cell-Biologic and Functional Analyses of Five New Aquaporin-2 Missense Mutations that Cause Recessive Nephrogenic Diabetes Insipidus J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2267 - 2277. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Thomas, B. Gut, G. Wendt-Nordahl, and J. Kiehn The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Go-Related Gene (HERG) Potassium Channels J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 543 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Baroudi, V. Pouliot, I. Denjoy, P. Guicheney, A. Shrier, and M. Chahine Novel Mechanism for Brugada Syndrome : Defective Surface Localization of an SCN5A Mutant (R1432G) Circ. Res., June 22, 2001; 88 (12): e78 - e83. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Bianchi, S. G. Priori, C. Napolitano, K. A. Surewicz, A. T. Dennis, M. Memmi, P. J. Schwartz, and A. M. Brown Mechanisms of IKs suppression in LQT1 mutants Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H3003 - H3011. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cui, A. Kagan, D. Qin, J. Mathew, Y. F. Melman, and T. V. McDonald Analysis of the Cyclic Nucleotide Binding Domain of the HERG Potassium Channel and Interactions with KCNE2 J. Biol. Chem., May 11, 2001; 276(20): 17244 - 17251. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Baroudi, S. Acharfi, C. Larouche, and M. Chahine Expression and Intracellular Localization of an SCN5A Double Mutant R1232W/T1620M Implicated in Brugada Syndrome Circ. Res., January 11, 2002; 90 (1): e11 - e16. [Abstract] [Full Text] [PDF] |
||||
![]() |
|